Recent Updates
Recently added Catalysts
SVRA Positive Sentiment

Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European Respiratory Society (ERS) Congress 2026

Monday, August 24, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Savara Inc. announced that data from the Phase 3 IMPALA-2 clinical trial of molgramostim will be presented at the ERS Congress 2026. The presentations include one oral and two poster formats, highlighting improvements in lung function, exercise capacity, and quality of life for patients with Autoimmune Pulmonary Alveolar Proteinosis. This recognition underscores the significance of the trial results.

Market Sentiment Analysis

POSITIVE FACTORS

  • Molgramostim shows continued improvement in lung function.
  • Positive impact on exercise capacity and quality of life.
  • Data accepted for presentation at a major congress.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+22%
120-day peak, hindsight
Typical move
10.4%
average across 3 past catalysts
Cash runway
~17 mo
Low dilution risk
Lead asset
MST-188
Phase 3 · Vaso-occlusive Crisis

Full Press Release Details

YARDLEY, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the acceptance of one oral presentation and two poster presentations on data from the Phase 3 IMPALA-2 clinical trial at the ERS Congress in Barcelona, Spain, September 5-9, 2026.“Collectively, these data show that molgramostim continues to improve lung function, exercise capacity, and quality of life in patients, while reductions in biomarkers of

Frequently Asked Questions

What is molgramostim used for?

Molgramostim is used to improve lung function in patients with Autoimmune Pulmonary Alveolar Proteinosis.

When will the ERS Congress take place?

The ERS Congress will be held from September 5-9, 2026.

How many presentations will Savara make at the congress?

Savara will present one oral presentation and two poster presentations.

What are the benefits of molgramostim according to the trial?

The trial shows improvements in lung function, exercise capacity, and quality of life.

ShareAdd on Google
Tags: SVRA Viatris Investor Conferences Healthcare Savara Molgramostim Phase 3 ERS Congress APAP
Last updated: Aug 24, 2026

Biotech snapshot

Cash runway
$173M liquidity · $10M/mo burn
~17 mo
Low dilution risk
Lead asset
MST-188Phase 3
Vaso-occlusive Crisis →

Catalyst track record

+22%
best trade around SVRA's most recent catalyst

Peak hindsight return over a 120-day window, across 3 tracked FDA/PDUFA catalysts for SVRA.

See every catalyst's timing & PoA →